Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00232206 · ClinicalTrials.gov registry record · Phase 2
Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer
A Phase 2 study, sponsored by Providence Health & Services.
- Terminated
- Registry status
- Phase 2
- Development phase
- 40
- Enrollment target
NCT00232206 is a Phase 2 study that was terminated before completion, run by Providence Health & Services. The registered enrollment target is 40 participants.
The verdict
NCT00232206, a Phase 2 study, was terminated before completion, sponsored by Providence Health & Services.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 40 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the response rate of treatment with two cycles of cisplatin and docetaxel chemotherapy prior to surgery (neoadjuvant) for early stage non-small cell lung cancer (NSCLC). Secondary objectives of this study include assessment of radiographic response rate by computed tomography (CT) scanning, overall survival, time to progression, rate of complete surgical removal, and adverse reactions. In addition, this study will test whether positron emission tomography (PET) imaging can predict a tumor response. Patients who have a response to chemotherapy may receive 2 additional cycles after recovering from surgery.
Interventions
- DRUG Neoadjuvant Therapy with Cisplatin Plus Docetaxel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2005-05 |
| Est. Completion | 2007-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00232206
The ClinicalTrials.gov registry entry for NCT00232206 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Neoadjuvant Therapy with Cisplatin Plus Docetaxel is the first listed.
NCT00232206 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00232206 about?
NCT00232206 is a clinical study titled "Trial of Neoadjuvant Docetaxel and Cisplatin for Resectable Non-Small Cell Lung Cancer". The primary objective of this study is to assess the response rate of treatment with two cycles of cisplatin and docetaxel chemotherapy prior to surgery (neoadjuvant) for early stage non-small cell lung cancer (NSCLC). Secondary objectives of this study include assessment of radiographic response ra...
What is the current status of trial NCT00232206?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2005-05. Estimated completion is 2007-11.
What interventions are being tested in trial NCT00232206?
The interventions under investigation include: Neoadjuvant Therapy with Cisplatin Plus Docetaxel (DRUG).
Who is sponsoring clinical trial NCT00232206?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.